Andrea B. Apolo

Also affiliated with National Cancer Institute, National Cancer Institute, Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Papers

Driven by 49 papers — median percentile 0. Top paper: “Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma”.

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652

N/A

3.5DataRank · unranked

138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30202-3

N/A

3.0DataRank · unranked

89 citations

Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg +27 more

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

ESMO Open(2024)10.1016/j.esmoop.2024.102994

N/A

1.9DataRank · unranked

94 citations

Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah +15 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726

N/A

1.1DataRank · unranked

24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer

Nature Communications(2024)10.1038/s41467-024-45132-2

N/A

0.988DataRank · unranked

35 citations

Karthik Reddy Kami Reddy, Yang Yuntao, Yuen San Chan, Danthasinghe Waduge Badrajee Piyarathna, Lacey E. Dobrolecki +19 more

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial

European Journal of Cancer(2022)10.1016/j.ejca.2022.09.020

N/A

0.795DataRank · unranked

18 citations

Thomas Powles, Bernard Escudier, Mauricio Burotto, Joshua Zhang, Burçin Şimşek +4 more

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Annals of Oncology(2025)10.1016/j.annonc.2025.09.006

N/A

0.719DataRank · unranked

18 citations

Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B. Apolo, María T. Bourlon +16 more

A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale

Future Oncology(2025)10.1080/14796694.2025.2480534

N/A

0.165DataRank · unranked

2 citations

Elias Chandran, Saad Atiq, Andre R. Kydd, Daniel M. Girardi, Lisa Ley +14 more

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder

PLoS ONE(2021)10.1371/journal.pone.0241766

N/A

0DataRank · unranked

7 citations

Molly M. Lee, Dinuka M. De Silva, Arpita Singha Roy, Cara E. Wright, Tiffany K. Wong +7 more

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.3

N/A

0DataRank · unranked

9 citations

Daniel M. Girardi, Scot A. Niglio, Rosa Maria Nadal, Lisa M. Cordes, Seth M. Steinberg +15 more

A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4599

N/A

0DataRank · unranked

4 citations

Daniel M. Girardi, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz +15 more

A pilot clinical trial of genomic-based therapy assignment with co-expression extrapolation (COXEN) in advanced/metastatic urothelial carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.452

N/A

0DataRank · unranked

0 citations

Rosa Maria Nadal, Lisa M. Cordes, Seth M. Steinberg, Nicole N. Davarpanah, Rene Costello +12 more

Predicting cancer immunotherapy response from gut microbiomes using machine learning models

Oncotarget(2022)10.18632/oncotarget.28252

N/A

0DataRank · unranked

43 citations

Jay‐Hyun Jo, Zhiwei Zhang, Margaret A. MacGibeny, Jungmin Han, Diana M. Proctor +13 more

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

Med(2022)10.1016/j.medj.2022.11.001

N/A

0DataRank · unranked

42 citations

Eldad D. Shulman, Efrat Elis, Doreen S. Ben-Zvi, Omer Tirosh, Eden Maimon +26 more

MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays

Cell Reports Methods(2022)10.1016/j.crmeth.2021.100136

N/A

0DataRank · unranked

27 citations

Bryce Killingsworth, Julia Kepley, Tim Traynor, Sean Cook, Jason E. Savage +32 more

Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.440

N/A

0DataRank · unranked

7 citations

Jonathan Coleman, Nathan C. Wong, Daniel D. Sjoberg, Bernard H. Bochner, Guido Dalbagni +15 more

The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/- Ipi).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.452

N/A

0DataRank · unranked

0 citations

Katherine Lei, Nicholas Peter Verdini, Jeffrey Lin, Andy Vega, Scot A. Niglio +13 more

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad155

N/A

0DataRank · unranked

56 citations

Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha +50 more

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4607

N/A

0DataRank · unranked

3 citations

Nicholas I. Simon, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Rouf Banday +15 more

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1553

N/A

0DataRank · unranked

2 citations

Gal Dinstag, Eldad D. Shulman, Efrat Elis, Doreen S. Ben-Zvi, Omer Tirosh +15 more

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4571

N/A

0DataRank · unranked

1 citations

Scot A. Niglio, Elias Chandran, Giovanni Maria Iannantuono, Salah Boudjadi, Rouf Banday +15 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

(2023)10.1158/1078-0432.c.6529986

N/A

0DataRank · unranked

0 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16573

N/A

0DataRank · unranked

0 citations

Nicholas I. Simon, Elias Chandran, Katherine Lei, Nicholas Peter Verdini, Jeffrey Lin +15 more

Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4600

N/A

0DataRank · unranked

0 citations

Rod Carlo Columbres, Elias Chandran, Scot A. Niglio, Lisa M. Cordes, Lisa Ley +9 more

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16506

N/A

0DataRank · unranked

0 citations

Elias Chandran, Nicholas I. Simon, Lisa Ley, Lisa M. Cordes, Tzu-fang Wang +13 more

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis

BMJ Oncology(2024)10.1136/bmjonc-2024-000335

N/A

0DataRank · unranked

20 citations

Giovanni Maria Iannantuono, Saad Atiq, Dilara Akbulut, Ninet Sinaii, Nicholas I. Simon +11 more

New Therapeutic Horizons for Advanced or Metastatic Penile Cancer

Urologic Clinics of North America(2024)10.1016/j.ucl.2024.03.005

N/A

0DataRank · unranked

7 citations

Saad Atiq, Guru Sonpavde, Andrea B. Apolo, N. Simon

Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.08.003

N/A

0DataRank · unranked

4 citations

Carlos Riveros, Guru Sonpavde, Andrea B. Apolo, Aly‐Khan A. Lalani, Christopher J.D. Wallis +2 more

Microenvironment Shapes Small Cell Lung Cancer Neuroendocrine States and Presents Therapeutic Opportunities

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.09.579028

N/A

0DataRank · unranked

6 citations

Nobuyuki Takahashi, Rajesh Kumar, Samantha Nichols, Justin Malin, Allison L. Hunt +53 more

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma

UNC Libraries(2024)10.17615/6gs3-hm85

N/A

0DataRank · unranked

0 citations

Irina Ostrovnaya, Matthew I. Milowsky, Jonathan E. Rosenberg, Wassim Abida, Dean F. Bajorin +6 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0DataRank · unranked

16 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort

European Urology(2025)10.1016/j.eururo.2025.08.012

N/A

0DataRank · unranked

8 citations

Melissa Assel, Gopa Iyer, Scot A. Niglio, Bernard H. Bochner, Guido Dalbagni +28 more

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)

European Journal of Cancer(2025)10.1016/j.ejca.2025.115589

N/A

0DataRank · unranked

6 citations

Charalampos S. Floudas, Marco Filetti, Tommaso Giovagnoli, Stefano Sganga, Antonio Vitale +13 more

Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer

Urologic Oncology Seminars and Original Investigations(2025)10.1016/j.urolonc.2025.06.006

N/A

0DataRank · unranked

2 citations

Alon Lazarovich, Ragheed Saoud, Aaron Dahmen, Samuel Tremblay, Siobhan Telfer +20 more

Antibody–drug conjugates in rare genitourinary tumors: review and perspectives

Current Opinion in Oncology(2025)10.1097/cco.0000000000001141

N/A

0DataRank · unranked

0 citations

Md Shahid Sarwar, Saad Atiq, Raju Chelluri, Sandeep Gurram, Elias Chandran +8 more

Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.27.661875

N/A

0DataRank · unranked

0 citations

Sumeet Patiyal, Lipika R. Pal, Tiangen Chang, Sumona Biswas, Saugato Rahman Dhruba +36 more

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2891

N/A

0DataRank · unranked

48 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.0032

N/A

0DataRank · unranked

25 citations

Sandra G. Williams, Lawrence Yao, Suresh Maharjan, Julius Strauss, Elad Sharon +9 more

Assessing Contemporary Trends in Female Speakership within Urologic Oncology

Urology(2020)10.1016/j.urology.2020.08.006

N/A

0DataRank · unranked

15 citations

Adrien Bernstein, Amanda E. Jones, Juanita Crook, Andrea B. Apolo, Jennifer M. Taylor +7 more

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5039

N/A

0DataRank · unranked

3 citations

Daniel M. Girardi, Amir Mortazavi, Primo N. Lara, Sumanta K. Pal, Biren Saraiya +15 more

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5037

N/A

0DataRank · unranked

2 citations

Scot A. Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya +15 more

Autocrine Signaling by Receptor Tyrosine Kinases in Urothelial Carcinoma of the Bladder

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.15.341206

N/A

0DataRank · unranked

0 citations

Molly M. Lee, Dinuka M. De Silva, Arpita Singha Roy, Cara E. Wright, Tiffany K. Wong +7 more

Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review

Cancer Treatment Reviews(2021)10.1016/j.ctrv.2021.102333

N/A

0DataRank · unranked

48 citations

Amir Mortazavi, Lisa M. Cordes, Cristina Salabao, Susan Vandlik, Andrea B. Apolo +1 more

Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer

Urologic Oncology Seminars and Original Investigations(2021)10.1016/j.urolonc.2021.04.024

N/A

0DataRank · unranked

30 citations

Scot A. Niglio, Ashkan A. Malayeri, Jeffrey Lin, Sandeep Gurram, Heather J. Chalfin +5 more

Andrea B. Apolo

Indexed papers

Top data-sharing exemplar

Papers